Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Gains five cGMP manufacturing sites, including CMO operations
October 6, 2011
By: Tim Wright
Editor-in-Chief, Contract Pharma
Akorn, Inc. has entered into an agreement to acquire certain assets of Kilitch Drugs Ltd. (KDIL), a contract manufacturer of sterile injectables in India, and certain assets of NBZ Pharma Ltd., for approximately $52 million in cash plus future milestones payments totaling as much as $6 million. The assets include KDIL’s plant in Paonta Sahib in Himachal Pradesh, India, along with the associated contract manufacturing and international business, and certain product transfers from KDIL’s Navi Mumbai plant and NBZ Pharma. The acquisition, subject to regulatory approvals, is expected to close in the next three months. There are five cGMP manufacturing sites with approximately 230,000 sq. ft. of space associated with the acquisition. Two plants are completed and operational and three are under construction. The first operational plant manufactures injectables and is under expansion to add ophthalmic capabilities. The second plant has the capabilities to manufacture cephalosporins in various forms such as oral liquids and solids, as well as dry syrups and dry powder injectables. The three plants under construction are expected to be operational in 2012 and will have the capabilities to make carbapenems, hormonal and oncology related injectables. Raj Rai, Akorn’s chief executive officer, said, “We are excited about this acquisition as it expands both our capacities and capabilities for sterile injectables. With this platform we plan to offer a speed to market, high quality, comprehensive and cost effective solution to our domestic customers specifically for critical care products in categories such as anti-infectives and cancer that are consistently in short supply. Strategically, we will also establish a global footprint giving us access to the fast growing emerging markets.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !